Tag «approvals 2024»

Momelotinib

Momelotinib 414.47, C23H22N6O2, 1056634-68-4 FDA 2023, Ojjaara, To treat intermediate or high-risk myelofibrosis in adults with anemiaDrug Trials Snapshot N-(Cyanomethyl)-4-[2-(4-morpholin-4-ylanilino)pyrimidin-4-yl]benzamide N-(Cyanomethyl)-4-[2-[4-(4-morpholinyl)phenylamino]pyrimidin-4-yl]benzamide Jak2 tyrosine kinase inhibitor; Jak1 tyrosine kinase inhibitor Inflammatory disease; Myelofibrosis; Myeloproliferative disorder; Pancreatic ductal adenocarcinoma; Polycythemia vera CYT 387; CYT-387; momelotinib) GS-0387 CYT387 sulfate saltCAS No: 1056636-06-6 CYT387 Mesylate CAS No: 1056636-07-7 DI HCL SALT …

Linaprazan

Linaprazan CHINA 2024, APPROVALS 2024, AstraZeneca, CINCLUS, GERD, linaprazan glurate, for the treatment of moderate to severe GERD, 8-[(2,6-dimethylphenyl)methylamino]-N-(2-hydroxyethyl)-2,3-dimethylimidazo[1,2-a]pyridine-6-carboxamide Chemical structure of linaprazan glurate CAS No.: 1228559-81-6 , X842 Molecular formula C26H32N4O5 Molecular weight 480.556086540222 Accurate quality 480.237 5-[2-[[8-[(2,6-dimethylphenyl)methylamino]-2,3-dimethylimidazo[1,2-a]pyridine-6-carbonyl]amino]ethoxy]-5-oxopentanoic acid Linaprazan is a lipophilic, weak base with potassium-competitive acid blocking (P-CAB) activity. Linaprazan concentrates highly in the …

Pradefovir

Pradefovir WeightAverage: 423.79Monoisotopic: 423.0863188 Chemical FormulaC17H19ClN5O4P 9-[2-[[(2R,4S)-4-(3-chlorophenyl)-2-oxo-1,3,2λ5-dioxaphosphinan-2-yl]methoxy]ethyl]purin-6-amine 2R,4S-(+)-9-(2-(4-(3-chlorophenyl)-2-oxo-1,3,2-dioxaphosphorinan-2-yl)methoxyethyl)adenine HEPATITIS B VIRUS, APPROVALS 2024, CHINA 2024, Xi’an Xintong Pharmaceutical Research Co, Xinshumu Pradefovir Mesylate CAS No. : 625095-61-6, Remofovir mesylate 분자량 519.90 화학식 C18H23ClN5O7PS Pradefovir is a cyclodiester antiviral prodrug with specific activity against hepatitis B virus (HBV). Pradefovir is specifically metabolized in the liver by hepatic …

Cetagliptin

Cetagliptin CAS No. FREE FORM : 2243737-33-7 C18H18F6N4O, 420.4 g/mol [ Cetagliptin Phosphate 2243737-33-7 ] 분자량 MW 518.35 화학식 MF C18H21F6N4O5P (3R)-3-amino-1-[(8R)-8-methyl-3-(trifluoromethyl)-6,8-dihydro-5H-imidazo[1,5-a]pyrazin-7-yl]-4-(2,4,5-trifluorophenyl)butan-1-one (3R)-3-amino-1-[(8R)-8-methyl-3-(trifluoromethyl)-6,8-dihydro-5H-imidazo[1,5-a]pyrazin-7-yl]-4-(2,4,5-trifluorophenyl)butan-1-one CHINA 2024, APPROVALS 2024, CGeneTec, DIABETES, RegisteredType 2 diabetes mellitus CHINA 2024 Cetagliptin (CGT-8012) is an orally bioavailable, dipeptidyl peptidase 4 enzyme (DPP-4) inhibitor (‘gliptin’) class drug. It was designed as an antihyperglycemic agent …

Cofrogliptin

Cofrogliptin HSK 7653 (2R,3S,5R,6S)-2-(2,5-difluorophenyl)-5-(2-methylsulfonyl-4,6-dihydropyrrolo[3,4-c]pyrazol-5-yl)-6-(trifluoromethyl)oxan-3-amine APPROVALS 2024, CHINA 2024, Haisco Pharmaceutical Group Co, Beichangping, DIABETES Cofrogliptin (developmental name HSK7653) is a long-acting DPP4 inhibitor dosed once every two weeks.[1][2][3][4] Cofrogliptin (HSK7653) (compound 2), a tetrahydropyran derivative, is a potent oral dipeptidyl aminopeptidase 4 (DPP-4) inhibitor with Long-acting antidiabetic efficacy. Cofrogliptin (compound 2) has a great potential for type 2 diabetes mellitus (T2DM) . SYN …

Janagliflozin

Janagliflozin WeightAverage: 460.95Monoisotopic: 460.1652664 Chemical FormulaC25H29ClO6 China 2024, approvals 2024, Jilin Huisheng Biopharmaceutical Co, sihuan, SGLT2 inhibitors, Huiyoujing Janagliflozin is an SGLT2 inhibitor developed by Sihuan Pharmaceutical.[1][2][3][4][5][6] It is approved in China for the treatment of type 2 diabetes.[7] PAPER https://www.thieme-connect.de/products/ejournals/abstract/10.1055/s-0042-1751524 (71) (a) Wu, F. US9315438B2, 2016. (b) Wu, F. EP2891654A1, 2014. Initially, the two advanced intermediates were synthesized and then …

Zorifertinib

Zorifertinib AZD 3759 CAS 1626387-80-1, 67SX9H68W2 WeightAverage: 459.91Monoisotopic: 459.1473455 Chemical FormulaC22H23ClFN5O3 [4-(3-chloro-2-fluoroanilino)-7-methoxyquinazolin-6-yl] (2R)-2,4-dimethylpiperazine-1-carboxylate China 2024, APPROVALS 2024, Alpha Biopharma, ASTRA ZENECA, Zorifer, Zorifertinib (AZD3759) is a drug for the treatment of cancer.[1] In China, it was approved in 2024 for locally advanced or metastatic non-small-cell lung cancer (NSCLC) that has epidermal growth factor receptor exon 19 deletion or exon 21 L858R …

Garsorasib

Garsorasib Chemical Formula: C32H32F2N8O2 Exact Mass: 598.2616 Molecular Weight: 598.66 D 1553, Chia Tai Tianqing, CHINA 2024, APPROVALS 2024, Anfangning, Garsorasib is an orally available inhibitor of the oncogenic KRAS substitution mutation, G12C, with potential antineoplastic activity. Upon oral administration, garsorasib selectively targets the KRAS G12C mutant and inhibits KRAS G12C mutant-dependent signaling. KRAS, a member of the …

Fulzerasib

Fulzerasib GFH925 CAS No. : 2641747-54-6 Molecular Weight 617.07 Formula C32H30ClFN6O4 (7R)-16-chloro-15-(2-fluoro-6-hydroxyphenyl)-9-methyl-12-(4-methyl-2-propan-2-ylpyridin-3-yl)-5-prop-2-enoyl-2,5,9,12,14-pentazatetracyclo[8.8.0.02,7.013,18]octadeca-1(10),13,15,17-tetraene-8,11-dione (7R)-16-chloro-15-(2-fluoro-6-hydroxyphenyl)-9-methyl-12-(4-methyl-2-propan-2-ylpyridin-3-yl)-5-prop-2-enoyl-2,5,9,12,14-pentazatetracyclo[8.8.0.02,7.013,18]octadeca-1(10),13,15,17-tetraene-8,11-dione CHINA 2024, APPROVALS 2024, Innovent Biologics, DUPERT Fulzerasib (Dupert®; Innovent Biologics/GenFleet Therapeutics) is an orally active small molecule inhibitor of the KRAS G12C mutant protein being developed for the treatment of solid tumors harboring the KRAS G12C oncogenic driver mutation, including non-small cell …

Golidocitinib

Golidocitinib CAS 2091134-68-6 WeightAverage: 489.584Monoisotopic: 489.260071274 Chemical FormulaC25H31N9O2 (2R)-N-[3-[2-[(3-methoxy-1-methylpyrazol-4-yl)amino]pyrimidin-4-yl]-1H-indol-7-yl]-2-(4-methylpiperazin-1-yl)propanamide Approvals 2024, china 2024, DZD 4205, DIZAL, Gao Ruizhe, Golidocitinib is a pharmaceutical drug for the treatment of cancer. In June 2024, it was given conditional approval in China for the treatment of relapsed or refractory peripheral T-cell lymphoma.[1] Golidocitinib is classified as a Janus kinase inhibitor.[2][3] Golidocitinib is …